+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 60Years
All Genders
ID07242222

Assessing Erdosteine with Standard Therapy for Adults Aged 18 to 60 with Fatty Liver Disease

Led by Tanta University · Updated on 2025-12-10

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Nonalcoholic fatty liver disease NAFLD is a major cause of chronic liver disease worldwide, especially in developed countries. It involves fat buildup in the liver not caused by alcohol, viruses, drugs, or autoimmune conditions. This trial evaluates the safety and effectiveness of erdosteine, a drug with antioxidant and anti-inflammatory effects, in treating NAFLD patients. Participants will be randomly assigned to one of two groups one group receives standard conventional therapy plus a placebo, and the other receives standard therapy plus erdosteine 300 mg twice daily for three months. Standard therapy includes regular physical activity such as walking or cycling for 30-45 minutes at least five days a week, along with calorie restriction tailored for men and women based on weight. During the study, participants will be monitored over three months with ultrasounds to assess changes in liver fat accumulation and fibrosis risk scores. Researchers will track these primary outcomes to understand the impact of treatments. The trial includes adults aged 18 to 60 and involves double-blind procedures to ensure unbiased results.

CONDITIONS

Brief Title

Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here